Inhibikase Therapeutics (DB:IQT0) - Hisse Senedi Fiyatı, Haberler ve Analizler

IQT0 Stoklara Genel Bakış

A clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.

IQT0 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 90.16% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 14% oranında düşmesi öngörülüyor

Anlamlı bir piyasa değeri yok ( €7M )

Geliri 1 milyon ABD dolarından az ( $252K )

Hisse senetleri oldukça likit değildir

+ 3 daha fazla risk

Inhibikase Therapeutics, Inc. Rakipler

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€25.0m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Epigenomics

DB:ECX

€705.4k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Inhibikase Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.56
52 Haftanın En Yüksek Seviyesi	US$5.61
52 Haftanın En Düşük Seviyesi	US$2.56
Beta	0.78
11 Aylık Değişim	0%
3 Aylık Değişim	-82.48%
1 Yıllık Değişim	-89.58%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-98.26%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IQT0	DE Biotechs	DE Pazar
7D	0%	0.7%	1.1%
1Y	-89.6%	-17.7%	12.5%

Getiri vs. Endüstri: IQT0 geçen yıl % -17.7 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: IQT0 geçen yıl % 12.5 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IQT0's price volatile compared to industry and market?
IQT0 volatility
IQT0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: IQT0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IQT0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	7	Milton Werner	www.inhibikase.com

Inhibikase Therapeutics, Inc. Temel Bilgiler Özeti

Inhibikase Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IQT0 temel i̇stati̇sti̇kler
Piyasa değeri	€6.98m
Kazançlar(TTM)	-€18.01m
Gelir(TTM)	€238.24k

29.3x

P/S Oranı

-0.4x

F/K Oranı

IQT0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IQT0 gelir tablosu (TTM)
Gelir	US$251.79k
Gelir Maliyeti	US$13.43m
Brüt Kâr	-US$13.17m
Diğer Giderler	US$5.86m
Kazançlar	-US$19.03m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.56
Brüt Marj	-5,232.12%
Net Kâr Marjı	-7,557.69%
Borç/Özkaynak Oranı	0%

IQT0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IQT0 Stoklara Genel Bakış

Ödüller

Risk Analizi

Inhibikase Therapeutics, Inc. Rakipler

XTRA:CNW

€6.5m

XTRA:MDG1

€25.0m

BST:BPXA

€772.4k

DB:ECX

€705.4k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Inhibikase Therapeutics, Inc. announced that it has received $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. announced that it expects to receive $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. Announces Board Changes

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Recent updates

Inhibikase Therapeutics, Inc. announced that it has received $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. announced that it expects to receive $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. Announces Board Changes

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

Hissedar Getirileri